Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
February 15 2017 - 6:41PM
Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference
call with investors on Thursday, February 16,
2017 at 8 a.m., EST. Investors are invited to dial
into the conference call hosted by Nessan Bermingham, Ph.D.,
chief executive officer and founder, Jose E. Rivera, executive vice
president and general counsel, and Graeme Bell, chief financial
officer.
To participate on the day of the call, dial 844-882-7840 and use
Conference ID# 74650186, approximately five minutes before the
call. International callers, please dial +1 574-990-9827 and use
Conference ID# 74650186.
The call will be available for replay from February 16 to
March 18, 2017. The replay number is 855-859-2056, Conference ID#
74650186. International callers, please dial +1 404-537-3406,
Conference ID# 74650186.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on the
development of proprietary, potentially curative therapeutics using
the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. Our combination of deep scientific, technical and
clinical development experience, along with our leading
intellectual property portfolio, puts us in a unique position to
unlock broad therapeutic applications of the CRISPR/Cas9 technology
and create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us
on Twitter @intelliatweets.
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
(857) 706-1071
jenn.smoter@intelliatx.com
Investor Contact:
Graeme Bell
Chief Financial Officer
+1 857-706-1081
graeme.bell@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024